Graft-versus-host disease

The Lancet

Volumn 373, Issue 9674, 2009, Pages 1550-1561

  Ferrara, James LM ^a   Levine, John E ^a   Reddy, Pavan ^a   Holler, Ernst ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; BISPHOSPHONIC ACID DERIVATIVE; CALCINEURIN; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN; CYTOKINE; ETANERCEPT; FLUCONAZOLE; FOSCARNET; GANCICLOVIR; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; INSULIN; LYMPHOCYTE ANTIBODY; METHOTREXATE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; POSACONAZOLE; PREDNISONE; RAPAMYCIN; SIALIDASE INHIBITOR; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; UNINDEXED DRUG; VALGANCICLOVIR; VITAMIN D; VORICONAZOLE;

ADD ON THERAPY; ANAPHYLAXIS; ASPERGILLOSIS; ASPLENIA; AVASCULAR NECROSIS; BRAIN DISEASE; CANDIDIASIS; CELL TRANSPLANTATION; CHILL; CLINICAL FEATURE; CLINICAL TRIAL; CUSHING DISEASE; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEVER; GASTROINTESTINAL TRACT; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC CELL; HERPES ZOSTER; HIGH RISK POPULATION; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOMAGNESEMIA; INFECTION RISK; INFLUENZA; KIDNEY DYSFUNCTION; LIVER; LOW DRUG DOSE; LUNG; MUCOSA INFLAMMATION; MUSCLE WEAKNESS; MYOPATHY; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OSTEOPOROSIS; PATHOPHYSIOLOGY; PNEUMOCYSTOSIS; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; REVIEW; SKIN; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREMOR; VITAMIN SUPPLEMENTATION;

EID: 65349171937     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)60237-3     Document Type: Review

References (139)

1. Appelbaum F.R. Haematopoietic cell transplantation as immunotherapy. Nature 411 (2001) 385-389
2. Welniak L.A., Blazar B.R., and Murphy W.J. Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol 25 (2007) 139-170
3. Billingham R.E. The biology of graft-versus-host reactions. Harvey Lect 62 (1966-1967) 21-78
4. Korngold R., and Sprent J. Purified T cell subsets and lethal graft-versus-host disease in mice. In: Gale R.P., and Champlin R. (Eds). Progress in bone marrow transplantation (1987), Alan R Liss, New York 213-218
5. Kernan N.A., Collins N.H., Juliano L.L., Cartagena T.T., Dupont B.B., and O'Reilly R.J. Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-v-host disease. Blood 68 (1986) 770-773
6. Petersdorf E.W., Longton G.M., Anasetti C., et al. The significance of HLA-DRB1 matching on clinical outcome after HLA-A, B, DR identical unrelated donor marrow transplantation. Blood 86 (1995) 1606-1613
7. Krensky A.M., Weiss A., Crabtree G., Davis M.M., and Parham P. T-lymphocyte-antigen interactions in transplant rejection. N Engl J Med 322 (1990) 510-517
8. Loiseau P., Busson M., Balere M.L., et al. HLA association with hematopoietic stem cell transplantation outcome: the number of mismatches at HLA-A, -B, -C, -DRB1, or -DQB1 is strongly associated with overall survival. Biol Blood Marrow Transplant 13 (2007) 965-974
9. Ratanatharathorn V., Nash R.A., Przepiorka D., et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 92 (1998) 2303-2314
10. Cornetta K., Laughlin M., Carter S., et al. Umbilical cord blood transplantation in adults: results of the prospective cord blood transplantation (COBLT). Biol Blood Marrow Transplant 11 (2005) 149-160
11. Wagner J.E., Barker J.N., DeFor T.E., et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 100 (2002) 1611-1618
12. Barker J.N., and Wagner J.E. Umbilical-cord blood transplantation for the treatment of cancer. Nat Rev Cancer 3 (2003) 526-532
13. Bleakley M., and Riddell S.R. Molecules and mechanisms of the graft-versus-leukaemia effect. Nat Rev Cancer 4 (2004) 371-380
14. Goulmy E., Schipper R., Pool J., et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med 334 (1996) 281-285
15. Antin J.H., and Ferrara J.L. Cytokine dysregulation and acute graft-versus-host disease. Blood 80 (1992) 2964-2968
16. Cavet J., Middleton P.G., Segall M., Noreen H., Davies S.M., and Dickinson A.M. Recipient tumor necrosis factor-alpha and interleukin-10 gene polymorphisms associate with early mortality and acute graft-versus-host disease severity in HLA-matched sibling bone marrow transplants. Blood 94 (1999) 3941-3946
17. Lin M.T., Storer B., Martin P.J., et al. Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. N Engl J Med 349 (2003) 2201-2210
18. Dickinson A.M., and Charron D. Non-HLA immunogenetics in hematopoietic stem cell transplantation. Curr Opin Immunol 17 (2005) 517-525
19. Miller J.S., Soignier Y., Panoskaltsis-Mortari A., et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105 (2005) 3051-3057
20. Miller J.S., Cooley S., Parham P., et al. Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. Blood 109 (2007) 5058-5061
21. Velardi A., Ruggeri L., Moretta A., and Moretta L. NK cells: a lesson from mismatched hematopoietic transplantation. Trends Immunol 23 (2002) 438-444
22. Holler E., Rogler G., Brenmoehl J., et al. Prognostic significance of NOD2/CARD15 variants in HLA-identical sibling hematopoietic stem cell transplantation: effect on long-term outcome is confirmed in 2 independent cohorts and may be modulated by the type of gastrointestinal decontamination. Blood 107 (2006) 4189-4193
23. Martin P.J., Schoch G., Fisher L., et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood 76 (1990) 1464-1472
24. Sullivan K.M., Agura E., Anasetti C., et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 28 (1991) 250-259
25. Sullivan K.M., Mori M., Sanders J., et al. Late complications of allogeneic and autologous marrow transplantation. Bone Marrow Transplant 10 suppl 1 (1992) 127-134
26. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I-diagnosis and staging working group report. Biol Blood Marrow Transpl 11 (2005) 945-956
27. Griffith L.M., Pavletic S.Z., Lee S.J., Martin P.J., Schultz K.R., and Vogelsang G.B. Chronic graft-versus-host disease: implementation of the National Institutes of Health consensus criteria for clinical trials. Biol Blood Marrow Transplant 14 (2008) 379-384
28. Vogelsang G.B., Lee L., and Bensen-Kennedy D.M. Pathogenesis and treatment of graft-versus-host disease after bone marrow transplant. Ann Rev Med 54 (2003) 29-52
29. Ferrara J.L., and Deeg H.J. Graft-versus-host disease. N Engl J Med 324 (1991) 667-674
30. Goker H., Haznedaroglu I.C., and Chao N.J. Acute graft-vs-host disease: pathobiology and management. Exp Hematol 29 (2001) 259-277
31. Nevo S., Enger C., Swan V., et al. Acute bleeding after allogeneic bone marrow transplantation: association with graft versus host disease and effect on survival. Transplantation 67 (1999) 681-689
32. Ponec R.J., Hackman R.C., and McDonald G.B. Endoscopic and histologic diagnosis of intestinal graft-versus-host disease after marrow transplantation. Gastrointest Endosc 49 (1999) 612-621
33. Snover D.C., Weisdorf S.A., Vercellotti G.M., Rank B., Hutton S., and McGlave P. A histopathologic study of gastric and small intestinal graft-versus-host disease following allogeneic bone marrow transplantation. Hum Pathol 16 (1985) 387-392
34. Snover D.C., Weisdorf S.A., Ramsay N.K., McGlave P., and Kersey J.H. Hepatic graft versus host disease: a study of the predictive value of liver biopsy in diagnosis. Hepatology 4 (1984) 123-130
35. Fujii N., Takenaka K., Shinagawa K., et al. Hepatic graft-versus-host disease presenting as an acute hepatitis after allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 27 (2001) 1007-1010
36. Cahn J.-Y., Klein J.P., Lee S.J., et al. Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Société Française de Greffe de Moëlle et Thérapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study. Blood 106 (2005) 1495-1500
37. Anasetti C., Rybka W., Sullivan K.M., Banaji M., and Slichter S.J. Graft-v-host disease is associated with autoimmune-like thrombocytopenia. Blood 73 (1989) 1054-1058
38. Petersdorf E.W., Longton G., Anasetti C., et al. Donor-recipient disparities for HLA-C genes is a risk factor for graft failure following marrow transplantation from unrelated donors. Blood 86 suppl 1 (1995) 291a
39. Flomenberg N., Baxter-Lowe L.A., Confer D., et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood 104 (2004) 1923-1930
40. Lee S.J., Klein J.P., Barrett A.J., et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood 100 (2002) 406-414
41. Carlens S., Ringden O., Remberger M., et al. Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis. Bone Marrow Transplant 22 (1998) 755-761
42. Matzinger P. The danger model: a renewed sense of self. Science 296 (2002) 301-305
43. Shlomchik W.D., Couzens M.S., Tang C.B., et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 285 (1999) 412-415
44. Teshima T., Ordemann R., Reddy P., et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med 8 (2002) 575-581
45. Reddy P., Maeda Y., Liu C., Krijanovski O.I., Korngold R., and Ferrara J.L. A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses. Nat Med 11 (2005) 1244-1249
46. Kolb H.J., and Holler E. Adoptive immunotherapy with donor lymphocyte transfusions. Curr Opin Oncol 9 (1997) 139-145
47. Storb R., Rudolph R.H., and Thomas E.D. Marrow grafts between canine siblings matched by serotyping and mixed leukocyte culture. J Clin Invest 50 (1971) 1272-1275
48. Xun C.Q., Thompson J.S., Jennings C.D., Brown S.A., and Widmer M.B. Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice. Blood 83 (1994) 2360-2367
49. Hill G.R., and Ferrara J.L. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 95 (2000) 2754-2759
50. Hill G.R., Crawford J.M., Cooke K.R., Brinson Y.S., Pan L., and Ferrara J.L. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 90 (1997) 3204-3213
51. Choi S.W., Kitko C.L., Braun T., et al. Change in plasma tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic transplantation correlates with severity and incidence of GVHD and survival. Blood 112 (2008) 1539-1542
52. Murai M., Yoneyama H., Ezaki T., et al. Peyer's patch is the essential site in initiating murine acute and lethal graft-versus-host reaction. Nat Immunol 4 (2003) 154-160
53. Couriel D.R., Saliba R.M., Giralt S., et al. Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biol Blood Marrow Transplant 10 (2004) 178-185
54. Sorror M.L., Maris M.B., Storer B., et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood 104 (2004) 961
55. Duffner U.A., Maeda Y., Cooke K.R., et al. Host dendritic cells alone are sufficient to initiate acute graft-versus-host disease. J Immunol 172 (2004) 7393-7398
56. Sato K., Yamashita N., Baba M., and Matsuyama T. Regulatory dendritic cells protect mice from murine acute graft-versus-host disease and leukemia relapse. Immunity 18 (2003) 367-379
57. Le Blanc K., Frassoni F., Ball L., et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 371 (2008) 1579-1586
58. Medzhitov R., and Janeway Jr. C.A. Decoding the patterns of self and nonself by the innate immune system. Science 296 (2002) 298-300
59. Akira S., Uematsu S., and Takeuchi O. Pathogen recognition and innate immunity. Cell 124 (2006) 783-801
60. Dustin M.L. Role of adhesion molecules in activation signaling in T lymphocytes. J Clin Immunol 21 (2001) 258-263
61. Korngold R., and Sprent J. Features of T cells causing H-2-restricted lethal graft-vs.-host disease across minor histocompatibility barriers. J Exp Med 155 (1982) 872-883
62. Korngold R., and Sprent J. Surface markers of T cells causing lethal graft-vs-host disease to class I vs class II H-2 differences. J Immunol 135 (1985) 3004-3010
63. Cohen J.L., and Boyer O. The role of CD4+CD25hi regulatory T cells in the physiopathogeny of graft-versus-host disease. Curr Opin Immunol 18 (2006) 580-585
64. Zeng D., Lewis D., Dejbakhsh-Jones S., et al. Bone marrow NK1.1(-) and NK1.1(+) T cells reciprocally regulate acute graft versus host disease. J Exp Med 189 (1999) 1073-1081
65. Lowsky R., Takahashi T., Liu Y.P., et al. Protective conditioning for acute graft-versus-host disease. N Engl J Med 353 (2005) 1321-1331
66. Zeiser R., Nguyen V.H., Beilhack A., et al. Inhibition of CD4+CD25+ regulatory T cell function by calcineurin-dependent interleukin-2 production. Blood 108 (2006) 390-399
67. Fowler D.H., Kurasawa K., Smith R., Eckhaus M.A., and Gress R.E. Donor CD4-enriched cells of Th2 cytokine phenotype regulate graft-versus-host disease without impairing allogeneic engraftment in sublethally irradiated mice. Blood 84 (1994) 3540-3549
68. Yang Y.G., Dey B.R., Sergio J.J., Pearson D.A., and Sykes M. Donor-derived interferon gamma is required for inhibition of acute graft-versus-host disease by interleukin 12. J Clin Invest 102 (1998) 2126-2135
69. Ferrara J.L.M. Graft-versus-host disease. In: Hoffman R. (Ed). Hematology: basic principles and practice. 3rd edn (2006), WB Saunders, Philadelphia
70. Ferrara J.L., and Reddy P. Pathophysiology of graft-versus-host disease. Semin Hematol 43 (2006) 3-10
71. Krenger W., Falzarano G., Delmonte Jr. J., Snyder K.M., Byon J.C., and Ferrara J.L. Interferon-gamma suppresses T-cell proliferation to mitogen via the nitric oxide pathway during experimental acute graft-versus-host disease. Blood 88 (1996) 1113-1121
72. Reddy P., Teshima T., Kukuruga M., et al. Interleukin-18 regulates acute graft-versus-host disease by enhancing fas-mediated donor T cell apoptosis. J Exp Med 194 (2001) 1433-1440
73. Banovic T., MacDonald K.P., Morris E.S., et al. TGF-beta in allogeneic stem cell transplantation: friend or foe?. Blood 106 (2005) 2206-2214
74. van den Brink M.R., and Burakoff S.J. Cytolytic pathways in haematopoietic stem-cell transplantation. Nat Rev Immunol 2 (2002) 273-281
75. Wysocki C.A., Panoskaltsis-Mortari A., Blazar B.R., and Serody J.S. Leukocyte migration and graft-versus-host disease. Blood 105 (2005) 4191-4199
76. Waldman E., Lu S.X., Hubbard V.M., et al. Absence of beta7 integrin results in less graft-versus-host disease because of decreased homing of alloreactive T cells to intestine. Blood 107 (2006) 1703-1711
77. Welniak L.A., Kuprash D.V., Tumanov A.V., et al. Peyer's patches are not required for acute graft-versus-host disease after myeloablative conditioning and murine allogeneic bone marrow transplantation. Blood 107 (2006) 410-412
78. Iwasaki A., and Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 5 (2004) 987-995
79. Hill G.R., Teshima T., Rebel V.I., et al. The p55 TNF-alpha receptor plays a critical role in T cell alloreactivity. J Immunol 164 (2000) 656-663
80. Piguet P.F., Grau G.E., Allet B., and Vassalli P. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft versus host disease. J Exp Med 166 (1987) 1280-1289
81. Brown G.R., Lee E., and Thiele D.L. TNF-TNFR2 interactions are critical for the development of intestinal graft-versus-host disease in MHC class II-disparate (C57BL/6J->C57BL/6J x bm12)F1 mice. J Immunol 168 (2002) 3065-3071
82. Soiffer R. T cell depletion to prevent graft-vs-host disease. In: Blume K., Forman S.J., and Appelbaum F.R. (Eds). Thomas' hematopoietic cell transplantation. 3rd edn (2008), Blackwell, Oxford 221-233
83. Platzbecker U.U., Ehninger G.G., and Bornhäuser M.M. Allogeneic transplantation of CD34+ selected hematopoietic cells: clinical problems and current challenges. Leuk Lymphoma 45 (2004) 447-453
84. Urbano-Ispizua A., Rozman C., Martínez C., et al. Rapid engraftment without significant graft-versus-host disease after allogeneic transplantation of CD34+ selected cells from peripheral blood. Blood 89 (1997) 3967-3973
85. Wagner J.E., Thompson J.S., Carter S.L., and Kernan N.A. Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial. Lancet 366 (2005) 733-741
86. Bacigalupo A., Lamparelli T., Bruzzi P., et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 98 (2001) 2942-2947
87. Barge R., Starrenburg C.W.J., Falkenburg J.H.F., Fibbe W.E., Marijt E.W., and Willemze R. Long-term follow-up of myeloablative allogeneic stem cell transplantation using Campath "in the bag" as T-cell depletion: the Leiden experience. Bone Marrow Transplant 37 (2006) 1129-1134
88. Martin P.J., Hansen J.A., Torok-Storb B., et al. Effects of treating marrow with a CD3-specific immunotoxin for prevention of acute graft-versus-host disease. Bone Marrow Transplant 3 (1988) 437-444
89. Champlin R.E., Passweg J.R., Zhang M.J., et al. T cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T cell antibodies with narrow specificities. Blood 95 (2000) 3996
90. Chalandon Y., Roosnek E., Mermillod B., Waelchli L., Helg C., and Chapuis B. Can only partial T-cell depletion of the graft before hematopoietic stem cell transplantation mitigate graft-versus-host disease while preserving a graft-versus-leukemia reaction? A prospective phase II study. Biol Blood Marrow Transplant 12 (2006) 102-110
91. Goerner M., Weber-Nordt R., Hoepfner S., Benner A., Luft T., and Ho A.D. Addition of a low fixed number of CD3+ cells to CD34-enriched allografts: effects on engraftment, graft-versus-host disease, and survival after related and unrelated peripheral stem cell transplantation. J Hematother Stem Cell Res 12 (2003) 309-320
92. Ho V.T., Kim H.T., Li S., et al. Partial CD8+ T cell depletion of allogeneic peripheral blood stem cell transplantation is insufficient to prevent graft-versus-host disease. Bone Marrow Transplant 34 (2004) 987-994
93. Perez-Simon J.A., Diez-Campelo M., Martino R., et al. Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation. Br J Haematol 130 (2005) 394-403
94. Perez-Simon J.A., Kottaridis P.D., Martino R., et al. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood 100 (2002) 3121-3127
95. Delgado J., Thomson K., Russell N., et al. Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation study. Blood 107 (2006) 1724-1730
96. Guinan E.C., Boussiotis V.A., Neuberg D., et al. Transplantation of anergic histoincompatible bone marrow allografts. N Engl J Med 340 (1999) 1704-1714
97. Bacigalupo A. Antilymphocyte/thymocyte globulin for graft versus host disease prophylaxis: efficacy and side effects. Bone Marrow Transplant 35 (2005) 225-231
98. Kroger N., Zabelina T., Kruger W., et al. In vivo T cell depletion with pretransplant anti-thymocyte globulin reduces graft-versus-host disease without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors. Bone Marrow Transplant 29 (2002) 683-689
99. Remberger M., Mattsson J., and Ringdén O. Polyclonal anti-T cell globulin as part of the preparative regimen for pediatric allogeneic stem-cell transplantation. Pediatr Transplant 5 (2001) 285-292
100. Bacigalupo A., Lamparelli T., Barisione G., et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant 12 (2006) 560-565
101. Nash R.A., Antin J.H., Karanes C., et al. Phase III study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 96 (2000) 2062-2068
102. Qu L., and Kiss J.E. Thrombotic microangiopathy in transplantation and malignancy. Semin Thromb Hemost 31 (2005) 691-699
103. Wong R., Beguelin G.Z., de Lima M., et al. Tacrolimus-associated posterior reversible encephalopathy syndrome after allogeneic haematopoietic stem cell transplantation. Br J Haematol 122 (2003) 128-134
104. Bolwell B., Sobecks R., Pohlman B., et al. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplant 34 (2004) 621-625
105. Barker J.N., Weisdorf D.J., DeFor T.E., Blazar B.R., Miller J.S., and Wagner J.E. Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. Blood 102 (2003) 1915-1919
106. Baron F., Baker J.E., Storb R., et al. Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 104 (2004) 2254-2262
107. Burroughs L., Mielcarek M., Leisenring W., et al. Extending postgrafting cyclosporine decreases the risk of severe graft-versus-host disease after nonmyeloablative hematopoietic cell transplantation. Transplantation 81 (2006) 818-825
108. Cutler C., Kim H.T., Hochberg E., et al. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 10 (2004) 328-336
109. Alyea E.P., Li S., Kim H.T., et al. Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 14 (2008) 920-926
110. Cutler C., Henry N.L., Magee C., et al. Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 11 (2005) 551-557
111. Mielcarek M., Martin P.J., Leisenring W., et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 102 (2003) 756-762
112. Levine J.E., Uberti J.P., Ayash L., et al. Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy. Biol Blood Marrow Transplant 9 (2003) 189-197
113. Martino R., Iacobelli S., Brand R., et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 108 (2006) 836-846
114. MacMillan M.L., Weisdorf D.J., Davies S.M., et al. Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant 8 (2002) 40-46
115. MacMillan M.L., Weisdorf D.J., Wagner J.E., et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transplant 8 (2002) 387-394
116. Cragg L., Blazar B.R., Defor T., et al. A randomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease. Biol Blood Marrow Transplant 6 (2000) 441-447
117. Arai S., Margolis J., Zahurak M., Anders V., and Vogelsang G.B. Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment. Biol Blood Marrow Transplant 8 (2002) 155-160
118. Barr M.L., Meiser B.M., Eisen H.J., et al. Photopheresis for the prevention of rejection in cardiac transplantation. N Engl J Med 339 (1998) 1744-1751
119. Gatza E., Rogers C.E., Clouthier S.G., et al. Extracorporeal photopheresis reverses experimental graft-versus-host disease through regulatory T cells. Blood 112 (2008) 1515-1521
120. Greinix H.T., Knobler R.M., Worel N., et al. The effect of intensified extracorporeal photochemotherapy on long-term survival in patients with severe acute graft-versus-host disease. Haematologica 91 (2006) 405-408
121. Reddy P., and Ferrara J.L. Immunobiology of acute graft-versus-host disease. Blood Rev 17 (2003) 187-194
122. Levine J.E., Paczesny S., Mineishi S., et al. Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. Blood 111 (2008) 2470-2475
123. Koc S., Leisenring W., Flowers M.E., et al. Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood 100 (2002) 48-51
124. Couriel D., Hosing C., Saliba R., et al. Extracorporeal photopheresis for acute and chronic graft-versus-host disease: does it work?. Biol Blood Marrow Transplant 12 (2006) 37-40
125. Bashoura L., Gupta S., Jain A., et al. Inhaled corticosteroids stabilize constrictive bronchiolitis after hematopoietic stem cell transplantation. Bone Marrow Transplant 41 (2008) 63-67
126. Sano Y., Date H., Nagahiro I., Aoe M., and Shimizu N. Living-donor lobar lung transplantation for bronchiolitis obliterans after bone marrow transplantation. Ann Thorac Surg 79 (2005) 1051-1052
127. Marr K.A., Carter R.A., Boeckh M., Martin P., and Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 100 (2002) 4358-4366
128. Baddley J., Stroud T., Salzman D., and Pappas P. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis 32 (2001) 1319
129. Rovira M., Jimenez M., De La Bellacasa J., et al. Detection of aspergillus galactomannan by enzyme immunoabsorbent assay in recipients of allogeneic hematopoietic stem cell transplantation: a prospective study. Transplantation 77 (2004) 1260-1264
130. Center for Disease Control and Prevention, and Infectious Disease Society of America and ASBMT. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant 6 (2000) 1-83
131. Boeckh M., Kim H.W., Flowers M.E., Meyers J.D., and Bowden R.A. Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation: a randomized double-blind placebo-controlled study. Blood 107 (2006) 1800-1805
132. Machado C.M., Cardoso M., da Rocha I.F., Boas L.S.V., Dulley F.L., and Pannuti C.S. The benefit of influenza vaccination after bone marrow transplantation. Bone Marrow Transplant 36 (2005) 897-900
133. Machado C.M., Boas L.S.V., Mendes A., et al. Use of oseltamivir to control influenza complications after bone marrow transplantation. Bone Marrow Transplant 34 (2004) 111-114
134. Darabi K., Abdel-Wahab O., and Dzik W.H. Current usage of intravenous immune globulin and the rationale behind it: the Massachusetts General Hospital data and a review of the literature. Transfusion 46 (2006) 741-753
135. Kumar A., Teuber S.S., and Gershwin M.E. Intravenous immunoglobulin: striving for appropriate use. Int Arch Allergy Immunol 140 (2006) 185-198
136. Kulkarni S., Powles R., Treleaven J., et al. Chronic graft versus host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants. Blood 95 (2000) 3683-3686
137. Ljungman P., Engelhard D., de la Cámara R., et al. Vaccination of stem cell transplant recipients: recommendations of the infectious diseases working party of the EBMT. Bone Marrow Transplant 35 (2005) 737-746
138. Carpenter P.A., Hoffmeister P., Chesnut III C.H., et al. Bisphosphonate therapy for reduced bone mineral density in children with chronic graft-versus-host disease. Biol Blood Marrow Transplant 13 (2007) 683-690
139. Rizzo J.D., Wingard J.R., Tichelli A., et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European group for Blood and Marrow Transplantation, Center for International Blood and Marrow Transplant Research, and the American Society for Blood and Marrow Transplantation (EBMT/CIBMTR/ASBMT). Bone Marrow Transplant 37 (2006) 249-261